Tissue Genesis, a company focused on adult stem cell and regenerative medicine, has begun clinical trials for peripheral vascular disease (PVD) with adipose-derived adult stem cell-coated vascular grafts at the University of Louisville hospital. Tissue Genesis is the first to initiate a FDA-approved trial using the patient's own adipose-derived adult stem cells (ASCs) prepared at the point-of-care.
Tissue Genesis uses a Cell Isolation System which is a compact, automated desktop unit that utilizes liposuctioned adipose tissue to isolate millions of adult stem cells in about an hour. This proprietary enabling platform technology averages approximately 35 to 50 million stromal cells per 60 cc of adipose, which then can be potentially applied to a variety of unmet medical needs. The point-of-care Cell Isolation System, manufactured to the highest standards, is CE-marked and GMP-certified.